Ultragenyx Pharmaceutical Share Price (NASDAQ: RARE)

$29.96

▲

-0.34

(-1.12%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Ultragenyx Pharmaceutical Stock chart to analyse performance

Ultragenyx Pharmaceutical stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$29.72
Today's High:$30.43
$29.96
0.8%
Downside
Day's Volatility :2.33%
Upside
1.54%
52 Weeks Low:$25.81
52 Weeks High:$60.37
$29.96
13.85%
Downside
52 Weeks Volatility :57.25%
Upside
50.37%

Ultragenyx Pharmaceutical Stock Returns

Period	Ultragenyx Pharmaceutical Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-17.13%	3.6%	0.0%
6 Months	-27.41%	-7.7%	0.0%
1 Year	-46.24%	-12.6%	0.0%
3 Years	-38.21%	9.5%	-4.7%

Ultragenyx Pharmaceutical Inc. Key Stats

Check Ultragenyx Pharmaceutical key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$30.3
Open	$30.43
Today's High	$30.43
Today's Low	$29.72
Market Capitalization	$2.9B
Today's Volume	$1.3M
52 Week High	$60.37
52 Week Low	$25.81
Revenue TTM	$610.2M
EBITDA	$-469.6M
Earnings Per Share (EPS)	$-5.48
Profit Margin	-87.34%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-180.44%

Stock Returns calculator for Ultragenyx Pharmaceutical Stock including INR - Dollar returns

The Ultragenyx Pharmaceutical stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Ultragenyx Pharmaceutical investment value today

Current value as on today

₹58,049

Returns

₹41,951

(-41.95%)

Returns from Ultragenyx Pharmaceutical Stock

₹47,235 (-47.23%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Ultragenyx Pharmaceutical Stock

-54%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Ultragenyx Pharmaceutical Stock from India on INDmoney has decreased by -54% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Ultragenyx Pharmaceutical Inc.

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
10.60%
BlackRock Inc
6.39%
Sands Capital Management, LLC
4.09%
T. Rowe Price Associates, Inc.
2.99%
Baker Bros Advisors LP
2.88%
State Street Corp
2.72%

Analyst Recommendation on Ultragenyx Pharmaceutical Stock

Rating

Trend

Buy

88%Buy

11%Hold

0%Sell

Based on 27 Wall street analysts offering stock ratings for Ultragenyx Pharmaceutical(by analysts ranked 0 to 5 stars)

Ultragenyx Pharmaceutical Share Price Target

What analysts predicted

Upside of 187.22%

Target:

$86.05

Current:

$29.96

Ultragenyx Pharmaceutical share price target is $86.05, a slight Upside of 187.22% compared to current price of $29.96 as per analysts' prediction.

Ultragenyx Pharmaceutical Stock Insights

Price Movement
In the last 3 months, RARE stock has moved down by -12.0%
Increasing Revenue
Revenue is up for the last 2 quarters, 139.29M → 166.49M (in $), with an average increase of 16.3% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -151.08M → -114.95M (in $), with an average increase of 31.4% per quarter
RARE vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 117.2%
RARE vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 151.6%
Price to Sales
ForRARE every $1 of sales, investors are willing to pay $4.7, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Ultragenyx Pharmaceutical Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$103.7M	↑ 101.41%
Net Income	$-402.7M	↑ 103.8%
Net Profit Margin	-388.31%	↓ 4.56%

	FY20	Y/Y Change
Revenue	$271.0M	↑ 161.32%
Net Income	$-186.6M	↓ 53.67%
Net Profit Margin	-68.84%	↑ 319.47%

	FY21	Y/Y Change
Revenue	$351.4M	↑ 29.66%
Net Income	$-454.0M	↑ 143.36%
Net Profit Margin	-129.2%	↓ 60.36%

	FY22	Y/Y Change
Revenue	$363.3M	↑ 3.39%
Net Income	$-707.4M	↑ 55.81%
Net Profit Margin	-194.71%	↓ 65.51%

	FY23	Y/Y Change
Revenue	$434.2M	↑ 19.52%
Net Income	$-606.6M	↓ 14.25%
Net Profit Margin	-139.7%	↑ 55.01%

	FY24	Y/Y Change
Revenue	$560.2M	↑ 29.01%
Net Income	$-569.2M	↓ 6.17%
Net Profit Margin	-101.6%	↑ 38.1%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$108.8M	↓ 14.57%
Net Income	$-170.7M	↑ 38.55%
Net Profit Margin	-156.83%	↓ 60.13%

	Q2 FY24	Q/Q Change
Revenue	$147.0M	↑ 35.09%
Net Income	$-131.6M	↓ 22.9%
Net Profit Margin	-89.51%	↑ 67.32%

	Q3 FY24	Q/Q Change
Revenue	$139.5M	↓ 5.12%
Net Income	$-133.5M	↑ 1.46%
Net Profit Margin	-95.71%	↓ 6.2%

	Q4 FY24	Q/Q Change
Revenue	$164.9M	↑ 18.2%
Net Income	$-133.4M	↓ 0.1%
Net Profit Margin	-80.9%	↑ 14.81%

	Q1 FY25	Q/Q Change
Revenue	$139.3M	↓ 15.52%
Net Income	$-151.1M	↑ 13.27%
Net Profit Margin	-108.46%	↓ 27.56%

	Q2 FY25	Q/Q Change
Revenue	$166.5M	↑ 19.53%
Net Income	$-115.0M	↓ 23.91%
Net Profit Margin	-69.04%	↑ 39.42%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$94.7M	↑ 88.1%

	FY20	Y/Y Change
Profit	$264.9M	↑ 179.71%

	FY21	Y/Y Change
Profit	$335.4M	↑ 26.61%

	FY22	Y/Y Change
Profit	$335.0M	↓ 0.12%

	FY23	Y/Y Change
Profit	$389.0M	↑ 16.13%

	FY24	Y/Y Change
Profit	$483.5M	↑ 24.28%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$82.5M	↓ 28.51%

	Q2 FY24	Q/Q Change
Profit	$116.9M	↑ 41.75%

	Q3 FY24	Q/Q Change
Profit	$118.5M	↑ 1.36%

	Q4 FY24	Q/Q Change
Profit	$148.0M	↑ 24.91%

	Q1 FY25	Q/Q Change
Profit	$110.6M	↓ 25.24%

	Q2 FY25	Q/Q Change
Profit	$134.9M	↑ 21.92%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-345.4M	↑ 18.87%
Investing Cash Flow	$-13.0M	↓ 60.88%
Financing Cash Flow	$679.3M	↑ 101.66%

	FY20	Y/Y Change
Operating Cash Flow	$-132.2M	↓ 61.72%
Investing Cash Flow	$-179.1M	↑ 1273.73%
Financing Cash Flow	$600.3M	↓ 11.63%

	FY21	Y/Y Change
Operating Cash Flow	$-338.7M	↑ 156.16%
Investing Cash Flow	$-195.4M	↑ 9.07%
Financing Cash Flow	$118.6M	↓ 80.25%

	FY22	Y/Y Change
Operating Cash Flow	$-380.5M	↑ 12.33%
Investing Cash Flow	$-291.7M	↑ 49.28%
Financing Cash Flow	$501.2M	↑ 322.77%

	FY23	Y/Y Change
Operating Cash Flow	$-474.8M	↑ 24.8%
Investing Cash Flow	$168.0M	↓ 157.6%
Financing Cash Flow	$388.1M	↓ 22.56%

	FY24	Y/Y Change
Operating Cash Flow	$-414.2M	↓ 12.77%
Investing Cash Flow	$-17.8M	↓ 110.58%
Financing Cash Flow	$399.2M	↑ 2.86%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-190.7M	↑ 127.32%
Investing Cash Flow	$94.4M	↓ 188.24%
Financing Cash Flow	$-58.0K	↓ 100.02%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-77.0M	↓ 59.65%
Investing Cash Flow	$60.6M	↓ 35.87%
Financing Cash Flow	$384.9M	↓ 663787.93%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-67.0M	↓ 12.95%
Investing Cash Flow	$-275.5M	↓ 554.89%
Financing Cash Flow	$11.2M	↓ 97.1%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-79.5M	↑ 18.67%
Investing Cash Flow	$102.7M	↓ 137.29%
Financing Cash Flow	$3.2M	↓ 71.49%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-166.5M	↑ 109.39%
Investing Cash Flow	$119.9M	↑ 16.7%
Financing Cash Flow	$157.0K	↓ 95.07%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-108.3M	↓ 34.96%
Investing Cash Flow	$71.2M	↓ 40.63%
Financing Cash Flow	$83.6M	↑ 53179.62%

Ultragenyx Pharmaceutical Technicals Summary

Sell

Neutral

Buy

Ultragenyx Pharmaceutical is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Ultragenyx Pharmaceutical Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Ultragenyx Pharmaceutical Inc.	5.31%	-27.41%	-46.24%	-38.21%	-63.61%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Ultragenyx Pharmaceutical Inc.	NA	NA	-0.24	-5.06	-1.8	-0.22	NA	1.57
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Ultragenyx Pharmaceutical Inc.	Buy	$2.9B	-63.61%	NA	-87.34%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

Ultragenyx Pharmaceutical Dividend announcements

Ultragenyx Pharmaceutical Earnings
Ultragenyx Pharmaceutical’s price-to-earnings ratio stands at None

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.

Organization	Ultragenyx Pharmaceutical
Employees	1294
CEO	Dr. Emil D. Kakkis M.D., Ph.D.
Industry	Health Technology

Key Management of Ultragenyx Pharmaceutical Inc.

Name	Title
Dr. Emil D. Kakkis M.D., Ph.D.	Founder, President, CEO & Director
Mr. Howard Horn	Executive VP of Corporate Strategy & CFO
Mr. John Richard Pinion II	Chief Quality Operations Officer & Executive VP of Translational Sciences
Mr. Erik Harris M.B.A.	Executive VP & Chief Commercial Officer
Dr. Eric Crombez M.D.	Chief Medical Officer & Executive VP
Mr. Theodore A. Huizenga	Senior VP, Corporate Controller & Principal Accounting Officer
Ms. Karah Herdman Parschauer J.D.	Chief Legal Officer & Executive VP of Corporate Affairs
Mr. Ernie W. Meyer	Chief Human Resources Officer & Executive VP
Mr. Thomas R. Kassberg	Chief Business Officer & Executive VP
Mr. Vimal Srivastava	Senior Vice President of Business Development & Alliance Management

Important FAQs about investing in RARE Stock from India :

What is Ultragenyx Pharmaceutical share price today?

Ultragenyx Pharmaceutical share price today is $29.96 as on August 30, 2025 at 1:29 am IST at the close of the market. Ultragenyx Pharmaceutical share today touched a day high of $30.43 and a low of $29.72.

What is the 52 week high and 52 week low for Ultragenyx Pharmaceutical share?

Ultragenyx Pharmaceutical share touched a 52 week high of $60.37 and a 52 week low of $25.81. Ultragenyx Pharmaceutical stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $29.96, lower by 50.37% versus the 52 week high.

How to invest in Ultragenyx Pharmaceutical Stock (RARE) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Ultragenyx Pharmaceutical on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Ultragenyx Pharmaceutical Shares that will get you 0.0501 shares as per Ultragenyx Pharmaceutical share price of $29.96 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Ultragenyx Pharmaceutical Stock (RARE) from India?

Indian investors can start investing in Ultragenyx Pharmaceutical (RARE) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Ultragenyx Pharmaceutical stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Ultragenyx Pharmaceutical share’s latest price of $29.96 as on August 30, 2025 at 1:29 am IST, you will get 0.3338 shares of Ultragenyx Pharmaceutical. Learn more about fractional shares .

What are the returns that Ultragenyx Pharmaceutical has given to Indian investors in the last 5 years?

Ultragenyx Pharmaceutical stock has given -63.61% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?